Bio-Path Holdings, Inc. (BPTH) Issues Quarterly Earnings Results

Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.01, Bloomberg Earnings reports.

Shares of Bio-Path Holdings (BPTH) opened at 0.295 on Friday. The firm’s 50-day moving average price is $0.38 and its 200 day moving average price is $0.61. The company’s market cap is $29.52 million. Bio-Path Holdings has a 52 week low of $0.26 and a 52 week high of $1.72.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/08/12/bio-path-holdings-inc-bpth-issues-quarterly-earnings-results.html.

Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its stake in Bio-Path Holdings by 5,474.3% in the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after buying an additional 1,741,978 shares during the period. Tower Research Capital LLC TRC acquired a new stake in Bio-Path Holdings during the first quarter worth approximately $105,000. HighTower Advisors LLC raised its stake in Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock worth $1,043,000 after buying an additional 105,000 shares during the period. Sabby Management LLC raised its stake in Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock worth $569,000 after buying an additional 23,352 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares during the period. Institutional investors and hedge funds own 19.90% of the company’s stock.

Several analysts have weighed in on BPTH shares. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Bio-Path Holdings in a research note on Tuesday, July 4th. Zacks Investment Research downgraded Bio-Path Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th.

Bio-Path Holdings Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Earnings History for Bio-Path Holdings (NASDAQ:BPTH)

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply